Rep. Lisa C. McClain Purchases Shares of Repligen Corporation (NASDAQ:RGEN)

Key Points

• Rep. Lisa C. McClain purchased shares of Repligen Corporation (NASDAQ:RGEN) for an amount between $1,001 and $15,000 on July 22nd, 2023.
• Repligen reported earnings of $0.37 per share for the last quarter, missing the consensus estimate, although revenue increased by 14.8% year-over-year.
• Analysts have mixed ratings on Repligen stock, with a consensus price target of $169.45 and several firms giving it a "buy" rating.

Representative Lisa C. McClain (R-Michigan) recently bought shares of Repligen Corporation NASDAQ: RGEN. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Repligen stock on July 22nd. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
• Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
• Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
• Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
• Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.

Repligen Trading Down 0.4%

Shares of NASDAQ:RGEN opened at $126.64 on Friday. The company has a market cap of $7.12 billion, a P/E ratio of -506.54, a P/E/G ratio of 2.34 and a beta of 1.05. The stock's 50-day moving average is $122.58 and its 200-day moving average is $133.33. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59.

Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The company had revenue of $182.37 million during the quarter, compared to the consensus estimate of $174.62 million. During the same quarter in the previous year, the business posted $0.40 EPS. The firm's quarterly revenue was up 14.8% on a year-over-year basis. Equities research analysts predict that Repligen Corporation will post 1.72 earnings per share for the current year.

Insider Buying and Selling at Repligen

In related news, Director Martin D. Madaus purchased 1,800 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the acquisition, the director directly owned 1,800 shares in the company, valued at approximately $201,834. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD raised its stake in shares of Repligen by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock valued at $962,711,000 after acquiring an additional 430,039 shares during the last quarter. Champlain Investment Partners LLC increased its holdings in shares of Repligen by 8.6% in the fourth quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock valued at $222,176,000 after purchasing an additional 122,595 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Repligen by 1.3% in the first quarter. Alliancebernstein L.P. now owns 1,024,180 shares of the biotechnology company's stock valued at $130,317,000 after purchasing an additional 13,284 shares in the last quarter. Brown Capital Management LLC increased its holdings in shares of Repligen by 16.3% in the second quarter. Brown Capital Management LLC now owns 1,005,276 shares of the biotechnology company's stock valued at $125,036,000 after purchasing an additional 141,241 shares in the last quarter. Finally, Conestoga Capital Advisors LLC increased its holdings in shares of Repligen by 3.4% in the first quarter. Conestoga Capital Advisors LLC now owns 980,247 shares of the biotechnology company's stock valued at $124,727,000 after purchasing an additional 32,665 shares in the last quarter. Institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on RGEN shares. HC Wainwright reiterated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Monday, May 5th. Wall Street Zen cut shares of Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. JPMorgan Chase & Co. reduced their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research note on Tuesday, April 29th. Finally, Wells Fargo & Company cut their price target on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating for the company in a research note on Wednesday, July 30th. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $169.45.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027. McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election. Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.